Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.71 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MITF | O75030 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30904871 | 1.00 | NPC1 (0.71) | NPC1RAB9ATLR7L3MBTL1SMN1; SMN2 | |
| SCHEMBL17448399 | 0.85 | SMN1; SMN2 (0.71) | NPC1RAB9AL3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL2532524 | 0.85 | GRM4 (0.74) | NPC1RAB9ATLR7SMN1; SMN2MAPT | |
| SCHEMBL24824700 | 0.83 | RAB9A (1.00) | NPC1RAB9AL3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL1499586 | 0.81 | MAPT (0.61) | NPC1RAB9AL3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL3092361 | 0.81 | SMN1; SMN2 (1.00) | NPC1RAB9ASMN1; SMN2PKMMAPT | |
| SCHEMBL28172197 | 0.81 | TLR7 (0.71) | NPC1RAB9ATLR7SMN1; SMN2PKM | |
| SCHEMBL365595 | 0.80 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2PKMMAPT | |
| SCHEMBL14700783 | 0.80 | GRM4 (0.76) | TLR7GRM4 | |
| SCHEMBL15391396 | 0.80 | ABL1 (0.64) | NPC1RAB9AL3MBTL1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257182-A1 | Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | BOLEA CHRISTELLE | 2011-10-20 | — | — | US | claimed |
| US-20100137336-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-06-03 | — | — | US | claimed |
| US-8524726-B2 | Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2013-09-03 | — | — | US | disclosed |
| US-20130137704-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma, SA (CH) | 2013-05-30 | — | — | US | disclosed |
| US-20130131092-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma, SA (CH) | 2013-05-23 | — | — | US | disclosed |
| US-20110257182-A1 | Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | BOLEA CHRISTELLE | 2011-10-20 | — | — | US | disclosed |
| US-20100137336-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137704-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | NPC1 2148/4885RAB9A 1653/4885TLR7 271/4885 |
| US-20100137336-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | NPC1 2148/4885RAB9A 1653/4885TLR7 271/4885 |
| US-20110257182-A1 | Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | GRM4, GRM1, GRM3 | NPC1 2148/4885RAB9A 1653/4885TLR7 271/4885 |
| US-20130131092-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | NPC1 2148/4885RAB9A 1653/4885TLR7 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.